Ontario, Canada’s Emblem Corp. has been granted a permit from Health Canada to produce cannabis oils, the company announced in a press release. Gordon Fox, CEO, said the approval is “an incredibly important milestone” for the company, positioning them to “actively execute” the business plan for their pharmaceutical division.
“Cannabinoids have real therapeutic value, as evidenced by the products Cesamet, Marinol, and Sativex all having been approved as prescription drugs by Health Canada,” John H. Stewart, pharmaceutical division CEO, said in the release. “The active components in cannabis will be extracted, purified and incorporated into advanced formulations, in order to enhance their therapeutic utility.”
Emblem has invested $1 million CAD (USD $745,600) into their purification and extraction platform, including analytical equipment and a supercritical CO2 extractor. Additionally, the company plans on building a 2,500 square-foot dedicated extraction formulation laboratory on its Paris, Ontario property. They have “stockpiled a significant amount” of bud and trim for extraction, the release said. Three scientists who will pursue development and manufacture of “advanced dosage forms of cannabinoids” have been hired to work exclusively on the extraction project.
Emblem is licensed under Canada’s Access to Cannabis for Medical Purposes Regulations law.